कंपनी का अवलोकन
CNS Pharmaceuticals, Inc. operates as a clinical pharmaceutical entity dedicated to the research and development of anti-cancer drug candidates specifically designed for the treatment of brain and central nervous system tumors. The company functions within the healthcare sector, more precisely in the biotechnology industry, which focuses on the creation of biological medicines to address complex medical conditions. In terms of scale, the firm possesses a market capitalization of $1.73 million, while its annual revenue data is unavailable, and the specific employee count is not disclosed in the provided information. The extremely low market capitalization of $1.73 million indicates that the company is a small-cap entity with limited current revenue streams, suggesting it is likely still in an early stage of development or commercialization where market penetration is minimal.
वित्तीय स्वास्थ्य
The company reports a net income of $-15,850,564 for the trailing twelve months, with EBITDA standing at $-15,982,641, while the specific revenue figure for the trailing twelve months is unavailable. The substantial gap between the unavailable revenue figure and the significant negative net income reveals a cost structure where operating expenses, likely dominated by clinical trial costs for TPI 287 and Berubicin, far exceed any current revenue generation. The free cash flow is reported at $-6,958,225, which indicates that the company is burning cash and lacks immediate financial flexibility to fund operations without external capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability or that its accounting method for allocating costs results in zero margins across these specific line items. The company holds $7.20 million in cash against a debt obligation of $328,571, resulting in a debt-to-equity ratio of 7.26, which suggests a balance sheet that is heavily leveraged relative to its equity base despite holding significant cash reserves. The current ratio stands at 1.98, indicating that the company possesses 1.98 times more current assets than current liabilities, which points to adequate short-term liquidity to meet its immediate financial obligations. Furthermore, the return on equity is -296.3% and the return on assets is -115.3%, revealing that management effectiveness in generating returns for shareholders and utilizing assets is currently negative due to the company's ongoing losses.
मूल्यांकन आकलन
The trailing P/E ratio is unavailable, while the forward P/E is listed as -5.46, implying that the market expects the company to remain unprofitable in the immediate future rather than expecting a rapid return to earnings positivity. The price-to-book ratio is 0.12, which indicates that the company's market valuation is significantly below its book value, suggesting the market prices in high risks associated with its development stage or lack of commercial product. The price-to-sales ratio is unavailable, and the EV/EBITDA is 0.32, suggesting an enterprise valuation that is very low relative to its earnings power, though this metric must be interpreted with caution given the negative earnings. The 52-week high is $34.80 and the 52-week low is $2.06, meaning the stock is currently trading at a price that fluctuates within this wide range, reflecting significant uncertainty about its future trajectory. The beta value is 0.49, which means the stock's price volatility is less than half that of the broader market, indicating lower sensitivity to general market swings compared to large-cap stocks.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both unavailable, preventing a direct comparison of whether earnings are growing faster or slower than revenue, but the context of negative earnings suggests a focus on development rather than scaling profits. As a non-dividend payer, the company does not distribute a dividend yield or payout ratio, implying that any generated cash or retained earnings are theoretically available for reinvestment into clinical trials and research rather than being paid out to shareholders. The absence of dividend payments and the negative earnings profile indicate that the company prioritizes funding its drug development pipeline over providing current income to investors. Overall, the growth and income profile is characterized by a lack of current profitability, zero dividend income, and a reliance on external funding to sustain operations while developing anti-cancer candidates.